A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).

Sylvie Lorenzen,Jorge Riera Knorrenschild,Claudia Pauligk,Thorsten Oliver Goetze,Susanna Hegewisch-Becker,Jörg Seraphin,Peter C. Thuss-Patience,Hans-Georg Kopp,Tobias Dechow,Arndt Vogel,Kim Barbara Luley,D. Pink,M. Stahl,Frank Kullmann,Holger Hebart,Jens T. Siveke,Matthias Egger,Nils Homann,Stephan Probst,Salah-Eddin Al-Batran

A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).

2017

4027Background: There is a need for effective treatments in the second- or further line setting in advanced gastric cancer, especially for new agents. In the current trial we evaluated paclitaxel w...

Keywords:

Carcinoma
Physical therapy
Regimen
Platinum
General surgery
Paclitaxel
Medicine
esophagogastric junction
Gastroenterology
in patient
Internal medicine
advanced gastric cancer
Pathology
double blind

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations